ECE2018 Poster Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (34 abstracts)
Clinical features of a gastric neuroendocrine neoplasms type 1 series
Vasiliki Mavroeidi 1 , Marina Tsoli 1 , Aggeliki Karapanagioti 1 , Dimitrios Thomas 1 , Panagiotis Moschouris 1 , Charikleia Christakou 1 , Maria Chrysochoou 1 , Stavros Sougioultzis 2 , Ioannis Karoumpalis 3 , Maria Kaltsatou 1 , Georgios Nikolopoulos 1 , Gregory Kaltsas 1 & Krystallenia Alexandraki 1
1Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 2Gastroenterology Division, Department of Pathophysiology, ‘Laikon’ General Hospital, University of Athens, Athens, Greece; 3Department of Gastroenterology, Athens General Hospital ‘Georgios Gennimatas’, Athens, Greece.
Background: The aim of the study was to assess the clinical features of gastric neuroendocrine neoplasms type 1 (GNEN1).
Methods: We have analyzed the clinical data of the first 73 patients with GNEN1 from our registry.
Results: The mean age(±S.D.) of the patients (51 (68.9%) females) and the mean follow-up were 55±12.3 years and 28.8±42.2months, respectively. All patients had sporadic tumors and all were not functional. At diagnosis gastrin levels were 1086.4±946.7 pg/ml (<110). Anti-parietal cell antibodies (APCA) were positive in 91.1% (51) of the patients, autoimmune thyroid disease was found in 56.8%, and another autoimmune disease was reported in 21.9%. Median value of Ki-67 was 2 (interquantile range, IQR: 2, <1–20); 58.2% (39) patients had Ki-67≤2% and 41.8% (28) had Ki-67≤20% no neoplasm had Ki-67 >20%. The immunohistochemical analysis showed positivity for ghrelin in 3(4.1%), serotonin 2(2.7%), neuron specific enolase in 2, vasoactive intestinal peptide in 1 specimen and evidence of some ulceration (micro- or macro-) in 13 (17.8%) patients. Three (4.1%) patients had metastasis (two in liver and one in lymphnodes). Somatostatin receptor scintigraphy (SRS) was performed in 24 patients and was positive in 4 (16.7%). Regarding treatment, 16 patients received somatostatin analogues, 1 received everolimus, 12 (16.4%) patients were submitted in gastrectomy (total, partial or antrectomy). In the first year follow-up in 53.84%(21/39) GNEN-1 recurred [28.9% (6/21), Ki-67>2%], in the second year follow-up 56.3%(9/16) (12.5%(1/8), Ki-67>2%), in the fifth year follow-up 33.3%(4/12) (all Ki-67≤2%), while following years all cases had Ki-67%<2% that 2 (one with 5% and the other 3%). No death was reported in the studied population.
Conclusion: Our study showed that despite the fact that the prevalence of grade 2 GNEN1 is higher than previously, GNEN1 remains a benign disease.
Volume 56
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more